Idera Pharmaceuticals, Inc. IDRA
We take great care to ensure that the data presented and summarized in this overview for IDERA PHARMACEUTICALS, INC. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding IDRA
View allLatest Institutional Activity in IDRA
Top Purchases
Top Sells
About IDRA
Idera Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for rare disease indications in the United States. It offers Tilsotolimod (IMO-2125), a synthetic phosphorothioate oligonucleotide that acts as a direct agonist of TLR9 to stimulate the immune systems and for treating solid tumors, squamous cell carcinoma of the head and neck, and colorectal cancer. The company has a collaboration agreement with Bristol-Meyers Squibb. Idera Pharmaceuticals, Inc. was incorporated in 1989 and is headquartered in Exton, Pennsylvania.
Insider Transactions at IDRA
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 10
2023
|
Maxine Gowen |
SELL
Open market or private sale
|
Indirect |
51
-100.0%
|
$0
$0.51 P/Share
|
|
Aug 10
2023
|
Vincent Milano |
SELL
Open market or private sale
|
Direct |
3,283
-26.76%
|
$0
$0.53 P/Share
|
|
Jul 13
2023
|
Pillar Invest Corp > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
2,213
-1.32%
|
$2,213
$1.54 P/Share
|
|
Jul 12
2023
|
Pillar Invest Corp > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
3,605
-2.11%
|
$3,605
$1.58 P/Share
|
|
May 17
2023
|
Pillar Invest Corp > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
26,965
+13.64%
|
$26,965
$1.42 P/Share
|
|
May 17
2023
|
Atul Chopra > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
24,800
-0.34%
|
$24,800
$1.34 P/Share
|
|
May 16
2023
|
Atul Chopra > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
32,436
-0.65%
|
$32,436
$1.42 P/Share
|
|
May 15
2023
|
Atul Chopra > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
78,436
-0.4%
|
$78,436
$1.47 P/Share
|
|
May 12
2023
|
Atul Chopra > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
81,486
-0.28%
|
$81,486
$1.61 P/Share
|
|
May 11
2023
|
Atul Chopra > 10% Shareholder |
SELL
Open market or private sale
|
Indirect |
47,166
-0.16%
|
$47,166
$1.85 P/Share
|
|
Jan 17
2023
|
John Clayton Taylor CHIEF EXECUTIVE OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,341,764
+47.73%
|
-
|
|
Jan 17
2023
|
Daniel Salain CHIEF OPERATING OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
1,341,764
+47.73%
|
-
|
|
Jan 17
2023
|
Andrew R Jordan CHIEF STRATEGY OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
402,529
+47.11%
|
-
|
|
Jan 11
2023
|
Michael R Dougherty |
BUY
Grant, award, or other acquisition
|
Direct |
33,523
+8.2%
|
$0
$0.44 P/Share
|
|
Jan 06
2023
|
John J. Kirby CHIEF FINANCIAL OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
119,957
-27.46%
|
$0
$0.71 P/Share
|
|
Jan 06
2023
|
John J. Kirby CHIEF FINANCIAL OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
399,218
+47.75%
|
-
|
|
Jan 06
2023
|
Bryant David Lim SVP AND GENERAL COUNSEL |
SELL
Payment of exercise price or tax liability
|
Direct |
119,957
-27.92%
|
$0
$0.71 P/Share
|
|
Jan 06
2023
|
Bryant David Lim SVP AND GENERAL COUNSEL |
BUY
Grant, award, or other acquisition
|
Direct |
399,218
+48.16%
|
-
|
|
Jan 06
2023
|
Andrew R Jordan CHIEF STRATEGY OFFICER |
SELL
Payment of exercise price or tax liability
|
Direct |
73,940
-8.1%
|
$0
$0.71 P/Share
|
|
Jan 06
2023
|
Andrew R Jordan CHIEF STRATEGY OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
261,718
+22.28%
|
-
|